Soluble guanylate cyclase activators
AssigneeMerck Sharp & Dohme Corp.
InventorsJohn Q. Tan, Ronald M. Kim, John W. Mirc
Life of this patent
Estimating the term…
Abstract
This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.
Claims5
A compound of structural Formula I:
- and pharmaceutically acceptable salts thereof, wherein:
- X is selected from the group consisting of CH, and CR2;
- R1a and R1b are independently selected from the group consisting of —H, —F, —Cl, —Br, —CN, cyclopropyl, —C1-3alkyl optionally substituted with one to six of —F, and —O—C1-3alkyl optionally substituted with one to six of —F;
- R2 is selected from the group consisting of —F, —Cl, —Br, —CN, cyclopropyl, —C1-3alkyl optionally substituted with one to six of —F, and —O—C1-3alkyl optionally substituted with one to six of —F;
- R3a and R3b are independently selected from the group consisting of —H, —F, —Cl, —Br, —CN, —C1-3alkyl optionally substituted with one to six of —F, and —O—C1-3alkyl optionally substituted with one to six of —F;
- A is
- wherein R13 is selected from the group consisting of —H and —C1-6 alkyl;
- R4 is
- a heterocycle selected from the group consisting of:
- R5 is selected from the group consisting of —H, —F, —OH, —CF3, —OC1-3 alkyl and —OCF 3;
- j is an integer 1;
- k is an integer 1;
- R7 is selected from the group consisting of (a) —H, (b) —C1-6alkyl optionally substituted with one to six of —F, (c) —C1-3alkyl substituted with one or two of —OCH3,
- (d) —(CH2)0-1 —C3-6cycloalkyl optionally substituted with (i) one to three of —F or (ii) C1-3alkyl optionally substituted with one to three of —F,
- R8 is selected from the group consisting of —H, —F, —OH, and —C1-3alkyl optionally substituted with one to six of —F;
- R9 is selected from the group consisting of (a) —H, (b) —F, (c) —OH,
- (d) —C1-3alkyl optionally substituted with substituents selected from the group consisting of (i) —OH and (ii) one to six of —F,
- (e) —C3-bcycloalkyl optionally substituted with one to three of —F, and
- (f) —O—C1-3alkyl optionally substituted with —OH;
- R10 is selected from the group consisting of (a) —H, (b) —F, (c) —C1-3alkyl optionally substituted with with substituents selected from (i) —OH and (ii) one to six of —F, and
- (d) —O—C1-3alkyl;
- R11 is selected from the group consisting of (a) —H, (b) —C1-6alkyl optionally substituted with one to six of —F, (c) —C3-6cycloalkyl optionally substituted with —CH3, —CF3, —CN, —OH, or —NH2 or one to three of —F;
- R12a is selected from the group consisting of (a) —H, (b) —C1-6alkyl optionally substituted with one to six of —F, (c) —C3-6cycloalkyl optionally substituted with —CH3, —CF3, —CN, —OH, or one to three of —F;
- and
- R12 is selected from the group consisting of (a) —C1-6alkyl optionally substituted with one to six of —F, and (b) —C3-6cycloalkyl optionally substituted with one to three of —F.
Dependencies are inferred from the claim text.